

Research Article

Antidiabetic Activity of *Gnidia glauca* and *Dioscorea bulbifera*: Potent Amylase and Glucosidase Inhibitors

Sougata Ghosh,¹ Mehul Ahire,¹ Sumersing Patil,¹ Amit Jabgunde,² Meenakshi Bhat Dusane,¹ Bimba N. Joshi,³ Karishma Pardesi,⁴ Sanjay Jachak,⁵ Dilip D. Dhavale,² and Balu A. Chopade¹

¹Institute of Bioinformatics and Biotechnology, University of Pune, Pune 411007, India

²Garware Research Centre, Department of Chemistry, University of Pune, Pune 411007, India

³Animal Sciences Division, Agharkar Research Institute, Pune 411004, India

⁴Department of Microbiology, University of Pune, Pune 411007, India

⁵Department of Natural Products, National Institute of Pharmaceutical Education and Research, Mohali 160062, India

Correspondence should be addressed to Balu A. Chopade, directoribb@unipune.ac.in

Received 3 March 2011; Revised 29 April 2011; Accepted 11 May 2011

Academic Editor: Bhushan Patwardhan

Copyright © 2012 Sougata Ghosh et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Diabetes is a metabolic disorder affecting about 220 million people worldwide. One of the most critical complications of diabetes is post-prandial hyper-glycemia (PPHG). Glucosidase inhibitor and α -amylase inhibitors are class of compounds that help in managing PPHG. Low-cost herbal treatment is recommended due to their lesser side effect for treatment of diabetes. Two plants with significant traditional therapeutic potential, namely, *Gnidia glauca* and *Dioscorea bulbifera*, were tested for their efficiency to inhibit α -amylase and α -glucosidase. Stem, leaf, and flower of *G. glauca* and bulb of *D. bulbifera* were sequentially extracted with petroleum ether, ethyl acetate, and methanol as well as separately with 70% ethanol. Petroleum ether extract of flower of *G. glauca* was found to inhibit α -amylase significantly (78.56%). Extracts were further tested against crude murine pancreatic, small intestinal, and liver glucosidase enzyme which revealed excellent inhibitory properties. α -glucosidase inhibition provided a strong *in vitro* evidence for confirmation of both *G. glauca* and *D. bulbifera* as excellent antidiabetic remedy. This is the first report of its kind that provides a strong biochemical basis for management of type II diabetes using *G. glauca* and *D. bulbifera*. These results provide intense rationale for further *in vivo* and clinical study.

1. Introduction

Diabetes mellitus is a multifactorial disease. It is an endocrine and metabolic disorder characterized by chronic hyperglycemia [1]. Multiple biochemical impairments associate with micro- and macrovascular complications which is a major cause of morbidity and death in Diabetes mellitus [2, 3]. With the numbers of people affected by diabetes multiplying worldwide, the disease is taking an ever-increasing proportion of national and international health care strategies [4]. It is projected to become one of the world's main disablers and killers within the next 25 years [5–7]. The affected most are Asia and Africa, where DM rates are expected to rise by two- to threefolds by 2030 [8]. The modern medicines available for management of diabetes exert serious side effects such as hepatotoxicity, abdominal pain, flatulence, diarrhea, and

hypoglycemia [9, 10]. Drug resistance to these medicines is also reported after prolonged treatment. Therefore, apart from currently available therapeutic options, many herbal medicines have been recommended for treatment of diabetes [11]. Traditional herbal medicines have been used throughout the world for a range of diabetes [12]. The α -glucosidase inhibition significantly decreases post-prandial hyperglycemia (PPHG) in the treatment of type II diabetic (T2DM) patients [13]. Thus, discovery of a suitable inhibitor of glycosidase with minimum side effects poses a challenge in the search for a potent therapeutic agent. The search for improved and safe natural antidiabetic agents is underway, and the World Health Organization has also recommended the development of herbal medicines in this concern [11, 14]. In view of this background, we selected two important

medicinal plants, *Gnidia glauca* and *Dioscorea bulbifera* for the same.

G. glauca (Family-Thymelaeaceae) is used as traditional phytomedicine for treating sore throat, abdominal pain, wounds, burns, and snake bites [15]. Leaves have been applied to treat the contusions, swellings, back ache, and joint aches [16]. It is considered as a powerful vesicant. It also has agrochemical applications as a molluscicide, insecticide, piscicide, and even larvicidal agents [17–19]. It has been shown that several *Gnidia* species possess remarkable antineoplastic activity [20]. It is used as an antiviral agent against rabies in Ethiopia [21]. Its antidiabetic properties are not known.

D. bulbifera (Family-Dioscoreaceae) possess profound therapeutic potential. It is found throughout the warmer parts of India called as yam or air potato. It is widely used in traditional Indian and Chinese medicine in the treatment of sore throat, gastric cancer and carcinoma of rectum, and goiter [22, 23]. The various extracts of bulbs of the plant have been reported to be antihyperlipidemic [24], antitumor [25], antioxidant [26], anorexiatic [27], analgesic and anti-inflammatory [28], plasmid curing [29] and antihyperglycemic [30].

It is important to note that there are no reports about the antidiabetic activity of *G. glauca* till date. Similarly, no research has been carried out to identify the targets that can confirm and support the antidiabetic potential of *D. bulbifera*. Hence, we have investigated inhibitory effect of various extracts on commercially available porcine pancreatic α -amylase and glucosidases from pancreas, liver, and small intestine of Swiss mice. Furthermore, the inhibitory activity was confirmed against commercially available α -glucosidase from *Bacillus stearothermophilus*. HPLC fingerprints of the extracts were developed for 55 min and compared with the standards like gallic acid, quercetin, and diosgenin.

2. Methods

2.1. Chemicals. α -glucosidase and 4-nitrophenyl α -D-glucopyranoside were obtained from Sigma Aldrich, USA DNSA (dinitrosalicylic acid) was obtained from SRL Pvt. Ltd. (Mumbai, India). Petroleum ether, ethyl acetate, methanol, ethanol, dipotassium hydrogen phosphate (K_2HPO_4), potassium dihydrogen phosphate (KH_2PO_4), methanol, sodium potassium tartarate, sodium hydroxide (NaOH), were potassium from Qualigens, Mumbai, India. Porcine pancreatic α -amylase and sodium chloride (NaCl) was obtained from HiMedia Laboratories Mumbai, India. Acarbose was obtained from Bayer Pharmaceuticals Pvt. Ltd. (Mumbai, India). All the chemicals and reagents procured were of A.R. grade.

2.2. Plant Material. Fresh, leaves, stems, and flowers of *G. glauca* and bulbs of *D. bulbifera* were collected in the month of January from the Western Ghats, Maharashtra, India. Plant materials were identified and authenticated by botanist from National Research Institute of Ayurvedic Sciences, Central Council for Research in Ayurveda and Siddha, Government of Ayush, Ministry of Health and Family Welfare,

Department Of India New Delhi, Nehru Garden, Kothrud Pune, 411038. The specimen voucher number provided for the *G. glauca* was 327 and *D. bulbifera* was 860.

2.3. Preparation of Plant Extracts. Leaves, stems, and flowers of *G. glauca* were shade dried at room temperature. Bulbs of *D. bulbifera* were chopped into pieces and shade dried. Dried plant materials were subjected to size reduction to a coarse powder by using dry grinder. 100 g of each of the powder was packed into Soxhlet apparatus and extracted successively with petroleum ether, ethyl acetate and methanol at 80°C (yield 2, 8, and 8%, resp.). 100 g of each powdered plant material was also subjected to a cold extraction with 70% ethanol in distilled water. Petroleum ether, ethyl acetate and methanol extracts were evaporated to dryness under reduced pressure at 4°C in rotary evaporator while ethanolic extract was subjected to lyophilization and were stored in air-tight containers in refrigerator at 4°C. 20 mg dry weight of each crude extract was further reconstituted in 2 mL of 10% dimethyl sulfoxide (DMSO) in distilled water and 1 : 20 dilution of all these extracts were used for α -amylase and the glucosidase inhibition assays.

2.4. α -Amylase Inhibition Assay. Amylase activity was assayed using a modified Bernfeld method (1955) using starch as substrate. 50 μ g mL⁻¹ (O.D. 0.4 at 280 nm) of porcine pancreatic α -amylase was incubated with 1 mg mL⁻¹ samples at 37°C for 10 min [31]. One percent starch was used as substrate. α -amylase without any extract was used as control. Reducing sugar was estimated using DNSA assay at A 540 nm and the enzyme units were expressed as micro-molar per minute [32]. One unit of enzyme was defined as the amount of enzyme required to liberate 1 μ M of maltose under assay conditions. The final inhibition shown by different samples were compared with the standard inhibitor, acarbose [33]. The inhibitory activity was calculated by using the formula

$$\% \text{ Inhibition} = \frac{(A540_{\text{Control}} - A540_{\text{Test}})}{A540_{\text{Control}}} \times 100. \quad (1)$$

2.5. Glucosidase Inhibition Assay with Murine Pancreatic, Liver, and Small Intestinal Extracts. 10-week-old Swiss male mice weighing 20 gm were procured from National Toxicology Centre, Pune. Entire procedure was carried out with guidelines of Institutional Animal Ethical Committee. The mouse was starved for 12 h. Pancreas, liver, and small intestine tissues were excised and homogenized with 10 mM ice cold phosphate buffer containing 6 mM NaCl (1 : 10 dilution; w/v) and appropriate amount of protease inhibitors. Tissue homogenates were centrifuged for 10 min at 10,000 r.p.m. and the supernatant was taken as a source of enzyme that was diluted so as to get an absorbance of 0.4 (at 280 nm) [34]. Enzyme inhibition assay was carried out as described above. Percentage inhibition of the samples against pancreatic, small intestinal, and liver glucosidases was calculated [35].

2.6. α -Glucosidase Inhibition Assay. Glucosidase inhibition assay of extracts of the leaves, stem, and flower of *G. glauca*

and bulbs of *D. bulbifera* was carried out as per Sanap et al., 2010 [36]. In brief, 0.1 unit/mL of α -glucosidase was mixed with each of the samples and incubated for 1 h at 37°C. Enzyme action for α -glucosidase was initiated by addition of 2 mM *p*-nitrophenyl- α -D-glucopyranoside in 100 mM phosphate buffer of pH 6.8 and stopped by adding 2 mL of 0.1 M Na₂CO₃ after an incubation of 10 min at 37°C. α -Glucosidase activity was determined by measuring absorbance of the *p*-nitrophenol released from *p*NPG at 420 nm using Shimadzu Spectrophotometer UV-1601. One unit of glucosidase activity is defined as the amount of enzyme that hydrolyzed 1 μ M of *p*-nitrophenyl pyranoside per minute under assay condition.

2.7. Development of HPLC Fingerprints. A LC-6AD Shimadzu liquid chromatograph system with automated gradient controller, SPD-M20A Photo Diode Array UV-Vis detector and Phenomenex Luna 5 μ C-18 column (250 \times 4.6 mm ID) was used. 1 mL of HPLC grade methanol was added to 1 mg of sample and sonicated for 10 min followed by centrifugation at 3000 rpm for 15 min. The volume was made upto 10 mL with methanol and the solution was filtered through 0.22 μ m filter (Millipore). 20 μ L of sample was injected for development of the chromatogram for 55 min. A binary gradient with mobile phase containing: (solvent A) water-acetic acid (0.5% v/v) and (solvent B) acetonitrile: water-acetic acid (99.5–0.5) = 80 : 20 (v/v). The flow-rate was maintained constant at 1 mL/min and the solvent gradient elution program was as follows: 0–10 min, 90% A, 10% B; 10–20 min, 90–80% A, 10–20% B; 20–30 min, 80–60% A, 20–40% B; 30–40 min, 60–40% A, 40–60% B; 40–45 min, 40–30% A, 60–70% B; and 45–50 min, 30–90% A, 70–10% B.

2.8. Statistical Analysis. All values were expressed as mean \pm standard error of mean (S.E.M.), $n = 3$, and analyzed for ANOVA and two tailed Student's *t*-test ($P < 0.05$) [37].

3. Results

3.1. Porcine Pancreatic α -Amylase Inhibitory Activity of Plant Extracts. *In vitro* α -amylase inhibitory studies demonstrated that the extracts of both *G. glauca* as well as *D. bulbifera* had inhibitory activity. Porcine pancreatic α -amylase with 0.29 Umin⁻¹ was taken as 100% enzymatic activity. Significant inhibition was exhibited by petroleum ether extract of leaf ($IC_{50} = 34.88 \mu\text{g/mL}$), and flower ($IC_{50} = 31.82 \mu\text{g/mL}$) while *D. bulbifera* bulb showed 61.65% (Figure 1). Ethanolic extract of flower exhibited 77.93% inhibition with pure porcine α -amylase. Even ethyl acetate ($IC_{50} = 33.84 \mu\text{g/mL}$), and methanol ($IC_{50} = 33.92 \mu\text{g/mL}$) extract of flower showed very high inhibition. A significant inhibition of 73.39% was exhibited by ethyl acetate extract of *D. bulbifera* bulbs as well. Both ethyl acetate, and methanol extracts of leaf showed a considerable inhibition of 62.91 and 62.75% against α -amylase. Methanol and 70% ethanol extracts of *D. bulbifera* showed considerable inhibition as well. Thus, a significant inhibition was observed with extracts of flower of *G. glauca*




FIGURE 1: The percent α -amylase inhibition by plant extracts. Acarbose is taken as standard inhibitor. The data is indicated as the mean \pm SEM; [$n = 3$].

and bulbs of *D. bulbifera* bulbs; whereas the extracts of stem showed inhibition lower than both leaf and stem.

3.2. Murine Pancreatic Glucosidases Inhibitory Activity of Plant Extracts. Murine pancreatic enzyme activity exhibiting 0.24 Umin⁻¹ was taken as 100% enzymatic activity. Petroleum ether extract of *D. bulbifera* bulb exhibited 22.23% inhibition against murine pancreatic glucosidase, whereas *G. glauca* showed comparatively moderate inhibition of 16.18, 15.92, and 16.37% with stem, leaf, and flower, respectively. In case of ethyl acetate as well *D. bulbifera* bulb was found to be potent inhibitor showing an inhibition of 23.59%. *G. glauca* showed comparable inhibition with each of stem, leaf, and flower. Similar trend was observed in case of methanol and 70% ethanol extract where *D. bulbifera* showed 26% and 18.13%, respectively. Methanol extract of *D. bulbifera* showed significant difference with $P < 0.05$ as compared with other extracts (Table 1).

3.3. Murine Small Intestinal Glucosidases Inhibitory Activity of Plant Extracts. Murine small intestinal glucosidase with 0.12 Umin⁻¹ was taken as 100% enzymatic activity. Petroleum ether extract of *D. bulbifera* bulb ($IC_{50} = 33.62 \mu\text{g/mL}$) showed a maximum inhibition of 74.36% that was found to be more potent as compared to acarbose ($IC_{50} = 48.79 \mu\text{g/mL}$). Petroleum ether extract of *G. glauca* flower showed a maximum inhibition of 57.84%. Ethyl acetate ($IC_{50} = 43.22 \mu\text{g/mL}$), methanol ($IC_{50} = 43.47 \mu\text{g/mL}$), and 70% ethanol extract ($IC_{50} = 40.4 \mu\text{g/mL}$) of *G. glauca* flower showed inhibition comparable to acarbose (Table 2). Ethyl acetate extract of *D. bulbifera* bulb was found to be having an inhibition percentage of 51.41 which was significant as compared to both methanol and 70% ethanol extracts.

TABLE 1: Percent murine pancreatic glucosidase inhibition by plant extracts.

Acarbose [40.89 ± 1.03]	% Glucosidase inhibitory activity			
	Petroleum ether	Ethyl acetate	Methanol	Ethanol [70%]
<i>G. glauca</i>				
Stem	16.81 ± 0.25	19.32 ± 1.64	16.37 ± 1.35	13.12 ± 1.96
Leaf	15.92 ± 1.9	19.76 ± 1.94	18.76 ± 1.88	14.3 ± 1.03
Flower	16.37 ± 2.6	13.71 ± 2.11	18.87 ± 0.89	16.07 ± 2.48
<i>D. bulbifera</i>				
Bulb	22.23 ± 2.71	23.59 ± 0.71	26.1 ± 0.87	18.13 ± 0.15

The data is indicated as the mean ± SEM; [n = 3].

TABLE 2: Percent murine small intestinal glucosidase inhibition by plant extracts.

Acarbose [51.23 ± 0.89]	% Glucosidase inhibitory activity			
	Petroleum ether	Ethyl acetate	Methanol	Ethanol [70%]
<i>G. glauca</i>				
Stem	57.18 ± 3.75	55.55 ± 2.43	52.28 ± 3.59	47.38 ± 2.84
Leaf	52.61 ± 1.27	50 ± 3.53	49.34 ± 2.01	42.81 ± 3.28
Flower	57.84 ± 2.92	56.84 ± 1.44	57.51 ± 1.81	51.23 ± 0.81
<i>D. bulbifera</i>				
Bulb	74.36 ± 2.72	51.41 ± 0.75	50.24 ± 0.83	43.54 ± 0.18

The data is indicated as the mean ± SEM; [n = 3].

3.4. Murine Liver Glucosidases Inhibitory Activity of Plant Extracts. Murine liver glucosidase with 0.75 Umin^{-1} was taken as 100% enzymatic activity. *D. bulbifera* bulb showed a maximum inhibition of 73.36% amongst the petroleum ether extracts while ethyl acetate extract of stem of *G. glauca* showed a potent inhibition of 80%. Methanol extract of *G. glauca* leaf ($\text{IC}_{50} = 32.61 \mu\text{g/mL}$) showed excellent inhibition that was found to be most significant with $P < 0.05$ as compared with other plant extracts as well as acarbose (Table 3). Amongst the 70% ethanol extracts, *D. bulbifera* exhibited a maximum inhibition up to 53.3%.

3.5. α -Glucosidase Inhibitory Activity of Plant Extracts. 0.1 Umin^{-1} of α -glucosidase was taken as 100% enzymatic activity. Petroleum ether extract of *D. bulbifera* showed strong inhibitory potential with a percentage inhibition of 92.87% as compared to acarbose. Stem, leaf, and flower of *G. glauca* showed moderate inhibition of 43.54, 21.77 and 51.23%, respectively (Figure 2). Ethyl acetate extract of *D. bulbifera* bulb was found to be the strongest inhibitor showing an inhibition as high as 99.6%. Similarly, methanol and 70% ethanol extracts of *D. bulbifera* bulbs exhibited an inhibition of 98.81 and 79.27% which were most significant as compared to others.

3.6. HPLC Fingerprinting. In this study an HPLC method was developed to achieve shorter runtime (55 min) with gradual increase of organic phase (acetonitrile). Gallic acid, quercetin, and diosgenin were used as standards. HPLC fingerprinting showed the high content of diosgenin in the methanol extract of *D. bulbifera* bulb. A binary gradient system consisting of water-acetonitrile-acetic acid as mobile




FIGURE 2: The percent α -glucosidase inhibition by plant extracts. Acarbose is taken as standard inhibitor. The data is indicated as the mean ± SEM; [n = 3].

phase was able to separate the compounds in the extracts (Figure 3). The developed HPLC method was applied for detect of the marker compounds and to assess the number of unidentified peaks that indicated the variability in the phytochemical profile of the plant materials. The overlay HPLC fingerprints (See figure s21-24 is supplementary material available online at doi: 10.1155/2012/929051) were used to assess the sample similarity against a generated reference chromatogram. In case of *D. bulbifera* the variability was observed mostly in case of ethyl acetate and methanol

TABLE 3: Percent murine liver glucosidase inhibition by plant extracts.

Acarbose [37.33 ± 0.69]	% Glucosidase inhibitory activity			
	Petroleum ether	Ethyl acetate	Methanol	Ethanol [70%]
<i>G. glauca</i>				
Stem	70 ± 3.28	80 ± 0.56	70 ± 0.59	66.67 ± 1.09
Leaf	56.66 ± 2.71	80 ± 0.71	76.66 ± 0.87	73.33 ± 0.15
Flower	99 ± 1.12	93.33 ± 1.9	93.34 ± 1.5	90 ± 1.81
<i>D. bulbifera</i>				
Bulb	73.3 ± 2.73	40 ± 0.74	43.3 ± 0.81	53.3 ± 0.17

The data is indicated as the mean ± SEM; [n = 3].




FIGURE 3: A representative HPLC fingerprint of plant extract (a) *D. bulbifera* methanol extract and (b) HPLC chromatogram of a standard solution containing three marker compounds.

extracts. In case of *G. glauca* leaf the maximum diversity in the phytochemistry was characterized by twenty five peaks with different Rt values. Similarly, twenty-two peaks in the methanolic extract of *G. glauca* flower also notably indicated the presence of relatively high amount of phytochemicals of polar nature. Significant number of peaks in the ethyl acetate extract showed the dominance of the probable flavonoids or terpenoid compounds in both *D. bulbifera* and *G. glauca*. The chromatogram also showed several other unidentified peaks as shown in Table 4.

4. Discussion

Herbal extracts and herbal formulations, used in the Ayurvedic literature, have recently been reviewed and have gained importance for the control of T2DM. They are being used directly or indirectly for the preparation of many modern drugs [12]. Although *G. glauca* and *D. bulbifera* have been used for thousands of years as ingredients in Ayurvedic and Chinese traditional medicine, they have not gained much importance as medicines and one of the factors being lack of specific standards being prescribed for herbal medicines and supportive animal/clinical trials [38]. In the present study, we investigated both the plants for their possi-

ble significance in control of T2DM by glucosidase inhibitory activity. Plants have wide array of phytochemicals ranging from both nonpolar to polar. Thus, plant materials were sequentially extracted to ensure complete extraction of all non-polar as well as polar components and thereby inclusion of all components in the screening study. Plants are known to produce a large variety of glucosidase inhibitors that provides protection against insects and microbial pathogens [39, 40]. Therefore, plant extracts were analyzed for α -amylase inhibitory activity. Pancreatic and intestinal glucosidases are the key enzymes of dietary carbohydrate digestion and inhibitors of these enzymes may be effective in retarding glucose absorption to suppress PPHG. In T2DM, excessive hepatic glycogenolysis and gluconeogenesis is associated with decreased utilization of glucose by tissues being the fundamental mechanism underlying hyperglycemia [41]. The liver glucosidase inhibitors inhibit α -1,6-glucosidase of glycogen-debranching enzymes in the liver and reduce the glycogenolytic rate which increases the accumulation of glycogen stores in the liver [42, 43]. Inhibition of these enzyme systems decreases the current blood glucose levels in diabetic patient (as a short-term effect) and shows a small reduction in hemoglobin A_{1c} level (as a long-term effect).

TABLE 4: The retention time of chromatographic peak in the chromatogram of extracts of both *G. glauca* and *D. bulbifera* along with standards.

Peak no.	Retention time of plant extracts																									Standard		
	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	Gallic acid	Quercetin	Diosgenin									
1	1.675	34.977	1.827	23.854	23.859	23.964	25.542	24.625	46.84	1.479	1.482	1.831	46.571	19.298	19.313	19.313	5.298	38.382	47.714									
2	1.783	37.682	17.451	35.519	47.377	27.798	28.342	27.891	47.452	7.189	1.781	28.352	47.282	30.098	30.198	30.098	—	—	—									
3	32.526	38.463	23.969	38.39	—	30.052	28.501	28.353	—	28.041	1.867	28.695	—	30.45	34.315	30.452	—	—	—									
4	38.466	39.773	38.368	41.466	—	30.441	29.784	29.403	—	29.434	7.145	28.877	—	33.442	34.903	32.211	—	—	—									
5	46.99	41.556	45.786	47.495	—	30.833	30.579	30.201	—	30.239	25.512	30.683	—	34.316	35.488	34.381	—	—	—									
6	47.721	41.948	47.406	—	—	31.642	30.942	30.603	—	30.644	27.942	30.947	—	34.894	36.451	46.773	—	—	—									
7	—	46.251	49.786	—	—	32.22	31.357	30.996	—	31.051	28.062	31.591	—	35.505	37.76	—	—	—	—									
8	—	46.947	—	—	—	32.497	32.741	32.456	—	31.282	29.475	32.717	—	35.994	38.687	—	—	—	—									
9	—	47.683	—	—	—	32.917	32.939	32.683	—	31.96	29.804	37.067	—	37.765	46.74	—	—	—	—									
10	—	49.89	—	—	—	34.144	33.348	33.085	—	32.502	30.288	37.334	—	38.117	—	—	—	—	—									
11	—	—	—	—	—	34.359	35.132	34.915	—	33.13	30.696	37.96	—	38.69	—	—	—	—	—									
12	—	—	—	—	—	34.679	35.718	35.506	—	34.954	31.096	41.558	—	39.228	—	—	—	—	—									
13	—	—	—	—	—	34.923	36.639	36.437	—	35.168	31.334	—	—	46.261	—	—	—	—	—									
14	—	—	—	—	—	35.247	37.259	37.15	—	35.55	32.004	—	—	46.712	—	—	—	—	—									
15	—	—	—	—	—	36.176	37.504	37.335	—	35.744	32.534	—	—	50.066	—	—	—	—	—									
16	—	—	—	—	—	36.774	37.871	37.724	—	37.099	36.494	—	—	—	—	—	—	—	—									
17	—	—	—	—	—	37.04	38.857	38.706	—	37.372	37.098	—	—	—	—	—	—	—	—									
18	—	—	—	—	—	37.273	41.691	46.849	—	37.813	37.376	—	—	—	—	—	—	—	—									
19	—	—	—	—	—	37.443	47.555	47.569	—	38.008	38.002	—	—	—	—	—	—	—	—									
20	—	—	—	—	—	37.792	—	—	—	41.575	46.923	—	—	—	—	—	—	—	—									
21	—	—	—	—	—	38.285	—	—	—	45.361	47.588	—	—	—	—	—	—	—	—									
22	—	—	—	—	—	38.56	—	—	—	46.779	—	—	—	—	—	—	—	—	—									
23	—	—	—	—	—	40.345	—	—	—	—	—	—	—	—	—	—	—	—	—									
24	—	—	—	—	—	41.009	—	—	—	—	—	—	—	—	—	—	—	—	—									
25	—	—	—	—	—	47.029	—	—	—	—	—	—	—	—	—	—	—	—	—									

Sample numbers assigned to plant extracts are *D. bulbifera* bulb extracts (1) petroleum ether, (2) ethyl acetate, (3) methanol, (4) 70% ethanol; *G. glauca* leaf extracts (5) petroleum ether, (6) ethyl acetate, (7) methanol, (8) 70% ethanol; *G. glauca* flower extracts (9) petroleum ether, (10) ethyl acetate, (11) methanol, (12) 70% ethanol; *G. glauca* stem extracts (13) petroleum ether, (14) ethyl acetate, (15) methanol, and (16) 70% ethanol. (—) No peak.




FIGURE 4: Representative dose response curves for plant extracts. (a) Petroleum ether extracts against porcine pancreatic α -amylase; (b) ethyl acetate extracts against murine pancreatic glucosidase; (c) petroleum ether extracts against murine small intestinal glucosidase; (d) petroleum ether extracts against murine liver glucosidase; (e) ethyl acetate extracts against α -glucosidase.

Our investigation provides the first evidence of antidiabetic property of extracts of *G. glauca*. On the other hand, *D. bulbifera* is a comparatively well-studied plant system due to its anticancer and antioxidant activity [22, 26]. It is widely used in Asia as a rich and sustainable source of carbohydrate. Traditionally, it has gained importance for its antiobese and antihyperglycemic properties. However, there is no scientific evidence for this fact and hereby our investigation is a novel approach to identify the targets involved for lowering the glycemic index and the control of post-prandial hyperglycemia. In our study, for the first time a detailed biochemical basis of the antidiabetic activity is presented that involves the inhibition of not only the pure α -amylase and glucosidase as well as the crude murine enzymes which are the key players of the T2DM. Recently, a preliminary study has shown the antihyperglycemic and antihyperlipidemic activity of *D. bulbifera* on Wistar rats [30]. Hence, there is a need to find out the biochemical basis of lowering of glycemic index *in vitro*.

Plant extracts are known to be potent α -amylase inhibitors due to their rich phenolic content that bind to the reactive sites of enzymes, thus altering its catalytic activity [44]. It has been suggested that the mechanism of inhibition of α -amylase may occur through the direct blockage of the active centre at several subsites of the enzyme as also suggested for other inhibitors [45]. A significant variability in the levels of enzyme inhibition between the parts of the same plant evident in the dose response curves (Figure 4) suggests the phytochemical diversity among the parts resulting in variation in the antidiabetic property. Dose response curves for all extracts against, α -amylase, murine pancreatic, intestinal, liver glucosidases, and α -glucosidase are given in the supplementary information. Our study revealed that petroleum ether extract of *G. glauca* flower (78.56%) and methanolic extract of *D. bulbifera* bulbs (73.54%) were potent α -amylase inhibitors. Various herbal extracts like *Bougainvillea spectabilis* and *Trigonella foenum-graecum* seeds are known as α -amylase inhibitors showing 29.43% and 59%, respectively [35, 46]. Thus, *G. glauca* and *D. bulbifera* exhibited comparatively more efficient α -amylase inhibition.

The inhibition observed for extracts of *D. bulbifera* bulbs against murine pancreatic glucosidase was found to be comparable as earlier reports on other Indian medicinal plants such as *Linum usitatissimum* methanolic extract [35]. Similarly, leaf extract of *Murraya koenigii* and *Azadirachta indica* are reported to show 43.71% and 41.7% inhibition against murine small intestinal glucosidase, respectively. We found that, the methanolic extract of both *G. glauca* and *D. bulbifera* were found to be superior showing an inhibition at a range of 50–58%. Petroleum ether of *D. bulbifera* bulbs exhibited an inhibition of 73.3% against murine liver glucosidase which was more potent as compared to the maximum inhibition percent of *Bougainvillea spectabilis*, *Ocimum tenuiflorum*, and *Syzygium cumini* as reported earlier. However, extracts of *G. glauca* were found to have superior inhibitory property, particularly petroleum ether extract of flower that exhibited an inhibition in the range of 90–99% while methanol extract of leaf showed highest inhibition ($IC_{50} = 25.2 \mu\text{g/mL}$) against murine liver glucosidase. Ethanolic extract of *Andrographis paniculata* was reported to

inhibit α -glucosidase up to 89% only at significantly high concentration of 62.5 mg/mL [47]. However, methanolic extract of *G. glauca* leaf and ethyl acetate extract of *D. bulbifera* showed an inhibition of 99.19 and 99.6%, respectively, at considerably low concentrations (66.65 $\mu\text{g/mL}$). Moreover, the strong inhibition by methanol extract of flower ($IC_{50} = 53.74 \mu\text{g/mL}$) against the pure α -glucosidase from *Bacillus stearothermophilus* confirmed the antidiabetic property of *G. glauca* as well as its variability on the basis of the parts of plant selected. HPLC fingerprint indicated the presence of diosgenin in the methanolic extracts of *D. bulbifera* bulbs. The maximum number of peaks in the ethyl acetate fractions might be due to the rich flavonoids and terpenoid content in the plant materials.

We, for the first time, have explored *G. glauca* and *D. bulbifera* as potential glycosidase inhibitors. Presently, we have identified the targets of the extracts being the α -amylase and α -glucosidase as well as pancreatic, intestinal, and liver enzymes that are principally responsible for hyperglycemia in diabetes. They can further be studied and used as dietary supplement for controlling PPHG in type II diabetes.

5. Conclusions

G. glauca and *D. bulbifera* show significant inhibition with porcine pancreatic amylase and crude murine glucosidase as well as pure α -glucosidase. This may have beneficial effects in managing type II diabetes mellitus and could be used as effective herbal formulation in combinational therapy which can be taken up in further studies.

Acknowledgments





The authors acknowledge the National Center for Toxicology, Pune, India, for providing animals as source of crude enzyme. They are thankful to A. Ravi Kumar for helpful discussions. S. Ghosh is thankful to University of Pune for providing research stipend. M. B. Dusane and A. Jabunde are thankful to Council of Scientific and Industrial Research (CSIR, Government of India, New Delhi) for providing Senior Research Fellowship.

References

- [1] B. Nickavar and N. Yousefian, "Evaluation of α -amylase inhibitory activities of selected antidiabetic medicinal plants," *Journal für Verbraucherschutz und Lebensmittelsicherheit*, vol. 6, no. 2, pp. 191–195, 2011.
- [2] W. Xie, Y. Zhao, D. Gu, L. Du, G. Cai, and Y. Zhang, "Scorpion in combination with gypsum: novel antidiabetic activities in streptozotocin-induced diabetic mice by up-regulating pancreatic PPAR γ and PDX-1 expressions," *Evidence-Based Complementary and Alternative Medicine*, vol. 2011, Article ID 683561, 9 pages, 2011.
- [3] B. Berger, G. Stenström, and G. Sundkvist, "Incidence, prevalence, and mortality of diabetes in a large population: a report from the Skaraborg diabetes registry," *Diabetes Care*, vol. 22, no. 5, pp. 773–777, 1999.
- [4] World Health Organization, Diabetes Programme, 2008, <http://www.who.int/diabetes/en/>.

- [5] International Diabetes Federation, *Diabetes Atlas*, International Diabetes Federation, Brussels, Belgium, 3rd edition, 2006.
- [6] H. King, R. E. Aubert, and W. H. Herman, "Global burden of diabetes, 1995–2025: prevalence, numerical estimates, and projections," *Diabetes Care*, vol. 21, no. 9, pp. 1414–1431, 1998.
- [7] P. Zhang, X. Zhang, J. Brown et al., "Global healthcare expenditure on diabetes for 2010 and 2030," *Diabetes Research and Clinical Practice*, vol. 87, no. 3, pp. 293–301, 2010.
- [8] J. E. Shaw, R. A. Sicree, and P. Z. Zimmet, "Global estimates of the prevalence of diabetes for 2010 and 2030," *Diabetes Research and Clinical Practice*, vol. 87, no. 1, pp. 4–14, 2010.
- [9] T. Fujisawa, H. Ikegami, K. Inoue, Y. Kawabata, and T. Ogihara, "Effect of two α -glucosidase inhibitors, voglibose and acarbose, on postprandial hyperglycemia correlates with subjective abdominal symptoms," *Metabolism: Clinical and Experimental*, vol. 54, no. 3, pp. 387–390, 2005.
- [10] S. K. Singh, P. K. Rai, D. Jaiswal, and G. Watal, "Evidence-based critical evaluation of glycemic potential of *Cynodon dactylon*," *Evidence-Based Complementary and Alternative Medicine*, vol. 5, no. 4, pp. 415–420, 2008.
- [11] World Health Organization, *WHO Traditional Medicine Strategy 2002–2005*, WHO, Geneva, Switzerland, 2002.
- [12] B. Odhav, T. Kandasamy, N. Khumalo, and H. Baijnath, "Screening of African traditional vegetables for their alpha-amylase inhibitory effect," *Journal of Medicinal Plants Research*, vol. 4, no. 14, pp. 1502–1507, 2010.
- [13] H. Gin and V. Rigalleau, "Post-prandial hyperglycemia. Post-prandial hyperglycemia and diabetes," *Diabetes and Metabolism*, vol. 26, no. 4, pp. 265–272, 2000.
- [14] V. Upathaya and K. Pandey, "Ayurvedic approach to diabetes mellitus and its management by indigenous resources," in *Diabetes Mellitus in Developed Countries*, J. S. Bajaj, Ed., pp. 375–377, Inter Print, New Delhi, India, 1984.
- [15] B. W. R. C. Amarajeewa, A. P. Mudalige, and V. Kumar, "Chemistry and mosquito larvicidal activity of *G. glauca*," *Proceedings of the Peradeniya University Research Sessions, Sri Lanka*, vol. 12, no. 1, pp. 101–102, 2007.
- [16] P. G. Kareru, G. M. Kenji, A. N. Gachanja, J. M. Keriko, and G. Mungai, "Traditional medicines among the Embu and Mbeere peoples of Kenya," *African Journal of Traditional, Complementary and Alternative Medicines*, vol. 4, no. 1, pp. 75–86, 2007.
- [17] R. P. Borris and G. A. Cordell, "Studies of the thymelaeaceae II. Antineoplastic principles of *Gnidia kraussiana*," *Journal of Natural Products*, vol. 47, no. 2, pp. 270–278, 1984.
- [18] K. Franke, A. Porzel, and J. Schmidt, "Flavone-coumarin hybrids from *G. socotrana*," *Phytochemistry*, vol. 61, no. 7, pp. 873–878, 2002.
- [19] K. Javaregowda and L. K. Naik, "Ovicidal properties of plant extracts against the eggs of teak defoliator, *hyblaea puera* cramer karnataka," *Journal of Agricultural Science*, vol. 20, no. 2, pp. 291–293, 2007.
- [20] S. M. Kupchan, Y. Shizuri, W. C. Sumner, H. R. Haynes, A. P. Leighton, and B. R. Sickles, "Isolation and structural elucidation of new potent antileukemic diterpenoid esters from *G. species*," *Journal of Organic Chemistry*, vol. 41, no. 24, pp. 3850–3853, 1976.
- [21] T. Teklehaymanot and M. Giday, "Ethnobotanical study of medicinal plants used by people in Zegie Peninsula, Northwestern Ethiopia," *Journal of Ethnobiology and Ethnomedicine*, vol. 3, article 12, 2007.
- [22] H. Gao, L. Wu, and M. Kuroyanagi, "Seven compounds from *D. bulbifera* L.," *Natural Medicines*, vol. 55, no. 5, p. 277, 2001.
- [23] S. Jiang, *Dictionary of Chinese Crude Drugs*, Shanghai Scientific and Technical Publishers, Shanghai, China, New Medical College edition, 1978.
- [24] M. -L. McKoy, F. Omoruyi, O. Simon, and H. Asemota, "Investigation of the effects of a sapogenin-rich preparation from a jamaican yam (*D. Sp.*) on blood cholesterol levels in rats," *Proceedings of the Western Pharmacology Society*, vol. 46, pp. 156–159, 2003.
- [25] H. Gao, M. Kuroyanagi, L. Wu, N. Kawahara, T. Yasuno, and Y. Nakamura, "Antitumor-promoting constituents from *D. bulbifera* L. in JB6 mouse epidermal cells," *Biological and Pharmaceutical Bulletin*, vol. 25, no. 9, pp. 1241–1243, 2002.
- [26] M. R. Bhandari and J. Kawabata, "Organic acid, phenolic content and antioxidant activity of wild yam (*D. spp.*) tubers of Nepal," *Food Chemistry*, vol. 88, no. 2, pp. 163–168, 2004.
- [27] M. N. Jindal, V. V. Kelkar, and R. B. Doctor, "The anorexiant activity of *Kalio-kund* (*D. bulbifera* Linn.), methylphenidate and cocaine in rats: a preliminary study," *The Indian Journal of Medical Research*, vol. 57, no. 6, pp. 1075–1080, 1969.
- [28] T. B. Nguuelefack, M. Mbiantcha, A. Kamanyi, R. B. Teponno, A. L. Tapondjou, and P. Watcho, "Analgesic and anti-inflammatory properties of extracts from the bulbils of *D. bulbifera* L. var *sativa* (Dioscoreaceae) in mice and rats," *Evidence-Based Complementary and Alternative Medicine*, vol. 2011, Article ID 912935, 2011.
- [29] V. Shriram, S. Jahagirdar, C. Latha et al., "A potential plasmid-curing agent, 8-epidiosbulbin E acetate, from *D. bulbifera* L. against multidrug-resistant bacteria," *International Journal of Antimicrobial Agents*, vol. 32, no. 5, pp. 405–410, 2008.
- [30] Z. Ahmed, M. Z. Chishti, R. K. Johri, A. Bhagat, K. K. Gupta, and G. Ram, "Antihyperglycemic and antidyslipidemic activity of aqueous extract of *D. bulbifera* tubers," *Diabetologia Croatica*, vol. 38, no. 3, pp. 63–72, 2009.
- [31] P. Bernfeld, "Amylase alpha and beta," *Methods Enzymol*, vol. 1, pp. 149–158, 1955.
- [32] G. L. Miller, "Use of dinitrosalicylic acid reagent for determination of reducing sugar," *Analytical Chemistry*, vol. 31, no. 3, pp. 426–428, 1959.
- [33] K. Suthindhiran, M. A. Jayasri, and K. Kannabiran, " α -glucosidase and α -amylase inhibitory activity of *Micromonospora* sp. VITSDK3 (EU551238)," *International Journal of Integrative Biology*, vol. 6, no. 3, pp. 115–120, 2009.
- [34] E. Galip, H. Afik, O. Omer, Y. Gul, C. Isil, and B. Yucel, "Leukotrienes in cerulein-induced acute pancreatitis in rats and effect of octreotide," *Turkish Journal of Gastroenterology*, vol. 10, no. 1, pp. 40–47, 1999.
- [35] M. Bhat, S. S. Zinjarde, S. Y. Bhargava, A. Ravikumar, and B. N. Joshi, "Antidiabetic Indian plants: a good source of potent amylase inhibitors," *Evidence-Based Complementary and Alternative Medicine*, vol. 2008, Article ID 810207, 6 pages, 2008.
- [36] S. P. Sanap, S. Ghosh, A. M. Jabgunde et al., "Synthesis, computational study and glycosidase inhibitory activity of polyhydroxylated conidine alkaloids—a bicyclic iminosugar," *Organic and Biomolecular Chemistry*, vol. 8, no. 14, pp. 3307–3315, 2010.
- [37] V. U. Pawar, S. Ghosh, B. A. Chopade, and V. S. Shinde, "Design and synthesis of harzialactone analogues: promising anticancer agents," *Bioorganic and Medicinal Chemistry Letters*, vol. 20, no. 24, pp. 7243–7245, 2010.

- [38] S. S. Gupta, "Prospects and perspectives of natural plants products in medicine," *Indian Journal of Pharmacology*, vol. 26, no. 1, pp. 1–12, 1994.
- [39] C. A. Ryan, "Proteinase inhibitor gene families: strategies for transformation to improve plant defenses against herbivores," *BioEssays*, vol. 10, no. 1, pp. 20–24, 1989.
- [40] S. Lu, P. Deng, X. Liu et al., "Solution structure of the major α -amylase inhibitor of the crop plant amaranth," *The Journal of Biological Chemistry*, vol. 274, no. 29, pp. 20473–20478, 1999.
- [41] A. Latner, "Carbohydrate metabolism: Abnormalities of post absorptive blood sugar level," in *Clinical Biochemistry*, p. 48, WB Saunders, Philadelphia, Pa, USA, 2nd edition, 1958.
- [42] M. Bollen and W. Stalmans, "The antiglycogenolytic action of 1-deoxynojirimycin results from a specific inhibition of the α -1,6-glucosidase activity of the debranching enzyme," *European Journal of Biochemistry*, vol. 181, no. 3, pp. 775–780, 1989.
- [43] Y. Yoshikuni, "Inhibition of intestinal α -glucosidase activity and postprandial hyperglycemia by moranoline and its N-alkyl derivatives," *Agricultural and Biological Chemistry*, vol. 52, no. 1, pp. 121–128, 1988.
- [44] F. Payan, "Structural basis for the inhibition of mammalian and insect α -amylases by plant protein inhibitors," *Biochimica et Biophysica Acta*, vol. 1696, no. 2, pp. 171–180, 2004.
- [45] P. P. McCue and K. Shetty, "Inhibitory effects of rosmarinic acid extracts on porcine pancreatic amylase *in vitro*," *Asia Pacific Journal of Clinical Nutrition*, vol. 13, no. 1, pp. 101–106, 2004.
- [46] R. Randhir and K. Shetty, "Improved α -amylase and *Helicobacter pylori* inhibition by fenugreek extracts derived via solid-state bioconversion using *Rhizopus oligosporus*," *Asia Pacific Journal of Clinical Nutrition*, vol. 16, no. 3, pp. 382–392, 2007.
- [47] R. Subramanian, M. Z. Asmawi, and A. Sadikun, "*In vitro* α -glucosidase and α -amylase enzyme inhibitory effects of *Andrographis paniculata* extract and andrographolide," *Acta Biochimica Polonica*, vol. 55, no. 2, pp. 391–398, 2008.



Hindawi
Submit your manuscripts at
<http://www.hindawi.com>

